ASRT Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -380280%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Altimmune, Inc.'s return on equity of -56.24%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 241.64%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 320.12%. Given that Altimmune, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Altimmune, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.519% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Altimmune, Inc. quarterly revenues of $5K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.36x versus 16,778.75x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Actinium Pharmaceuticals, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -5701.11%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 241.64%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 290.63%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.519% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.258%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.36x versus 443.68x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -12425.36%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 241.64%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 406.49%. Given that Perspective Therapeutics, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.519% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Assertio Holdings, Inc.'s net income of $11.4M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.36x versus 164.77x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 23.14% compared to Assertio Holdings, Inc.'s net margin of -36.3%. Assertio Holdings, Inc.'s return on equity of -25.86% beat Myomo, Inc.'s return on equity of -68.35%.

Assertio Holdings, Inc. has a consensus price target of $39.94, signalling upside risk potential of 241.64%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 410.26%. Given that Myomo, Inc. has higher upside potential than Assertio Holdings, Inc., analysts believe Myomo, Inc. is more attractive than Assertio Holdings, Inc..

Assertio Holdings, Inc. has a beta of 0.615, which suggesting that the stock is 38.519% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.158%.

Assertio Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Assertio Holdings, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.

Assertio Holdings, Inc. quarterly revenues are $49.5M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. Assertio Holdings, Inc.'s net income of $11.4M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, Assertio Holdings, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Assertio Holdings, Inc. is 4.36x versus 0.97x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.